azd6244
Stage IIIA Gallbladder Cancer
National Cancer Institute (NCI)Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Stage IIIA Gallbladder Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Lisata Therapeutics, Inc. | Phase 2 | B |
FLUOROURACILUM Lisata Therapeutics, Inc. | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Lisata Therapeutics, Inc. | Phase 2 | B |
Durvalumab Lisata Therapeutics, Inc. | Phase 2 | B |
Pembrolizumab Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | B |
View all 36 →
Same molecule, other indications
azd6244 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →